RxDoctor Payments Data

Mack Roach, MD

Therapeutic Radiology · San Francisco, CANPI 1770523359

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (42.2%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 7 manufacturers reported payments, led by Accuray Incorporated at 43.0% of the total. Reporting peaked in 2024 at $23,242 and has fallen 65.2% since, to $8,086 in 2025.

$40,293in general payments, 2019–2025

Across 32 payments — averaging $1259.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Accuray Incorporated$17K
  • Astellas Pharma US Inc$8K
  • Progenics Pharmaceuticals, Inc.$8K
  • Pfizer$3K
  • Merck$3K
  • Teleflex LLC$249
  • plus $45 from 1 others

What the payments were for

  • Consulting fees$16,99042%
  • Speaking & faculty fees$8,00020%
  • Travel & lodging$14,35036%
  • Food & beverage$9532%

General payments by program year

19
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Accuray Incorporated7$17,306
Astellas Pharma US Inc8$8,343
Progenics Pharmaceuticals, Inc.8$8,086
Pfizer2$3,264
Merck2$3,000
Teleflex LLC4$249
Mevion_medical_systems_inc1$45

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few therapeutic radiology providers in Californiato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$208,354
Medicare patients
153
Services billed
1,754

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OrgovyxRelugolix21$54,144
MyrbetriqMirabegron12$5,368
Tamsulosin Hcl164$2,352
Bicalutamide46$1,402
Alendronate Sodium17$140

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$8,343$5,36812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few therapeutic radiology providers in Californiaon file to place this against a meaningful peer group, so we don't.

Other therapeutic radiology in San Francisco

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →